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Abstract
Background: Uncertainty regarding comorbid illness, and ability to tolerate aggressive therapy
has led to minimal enrollment of elderly cancer patients into clinical trials and often substandard
treatment. Increasingly, comorbid illness scales have proven useful in identifying subgroups of
elderly patients who are more likely to tolerate and benefit from aggressive therapy. Unfortunately,
the use of such scales has yet to be widely integrated into either clinical practice or clinical trials
research.
Methods: This article reviews evidence for the validity of the Charlson Comorbidity Index (CCI)
in oncology and provides a Microsoft Excel (MS Excel) Macro for the rapid and accurate calculation
of CCI score. The interaction of comorbidity and malignant disease and the validation of the
Charlson Index in oncology are discussed.
Results: The CCI score is based on one year mortality data from internal medicine patients
admitted to an inpatient setting and is the most widely used comorbidity index in oncology. An MS
Excel Macro file was constructed for calculating the CCI score using Microsoft Visual Basic. The
Macro is provided for download and dissemination.
The CCI has been widely used and validated throughout the oncology literature and has
demonstrated utility for most major cancers. The MS Excel CCI Macro provides a rapid method
for calculating CCI score with or without age adjustments. The calculator removes difficulty in
score calculation as a limitation for integration of the CCI into clinical research. The simple nature
of the MS Excel CCI Macro and the CCI itself makes it ideal for integration into emerging electronic
medical records systems.
Conclusions: The increasing elderly population and concurrent increase in oncologic disease has
made understanding the interaction between age and comorbid illness on life expectancy
increasingly important. The MS Excel CCI Macro provides a means of increasing the use of the CCI
scale in clinical research with the ultimate goal of improving determination of optimal treatments
for elderly cancer patients.
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Background
Comorbid illness plays an essential, but poorly defined,
role in the diagnosis and management of malignant dis-
ease. Increasingly, the importance of measuring comor-
bidity in consistent and quantifiable ways is being
recognized. This movement has stemmed in part from a
growing consensus that comorbidity confounds the
results of clinical trials and limits the generalization of
results to older and sicker patients [1,2]. For various rea-
sons, however, the widespread integration of comorbidity
into clinical research has yet to be realized. It is our con-
tention that limited accessibility and cumbersome scoring
techniques are in part responsible for the limited use of
comorbidity indices. We believe that easily accessible
tools for calculating comorbidity can increase their use in
clinical research.
While multiple comorbidity indices are available, each
with unique advantages and disadvantages, no single
index has emerged as clearly superior to the others. In fact,
we have noted that a distinct trade-off between prognostic
utility and ease of use exists. We believe that a scoring sys-
tem that maximizes ease of use while maintaining prog-
nostic validity represents the optimal balance required for
use in clinical research. In addition, a scoring system that
can be easily integrated into an electronic medical record
will further promote the widespread use of comorbidity
data. We have, therefore, chosen to explore the use of the
Charlson Comorbidity Index (CCI) as the prototypical
comorbidity index in our department. The primary aim of
this article, therefore, is to provide an electronic Charlson
Comorbidity Index Scoring program and explain its devel-
opment and use. In an effort to provide the reader with
the context in which the electronic application was devel-
oped and should be used, the interaction of comorbidity
and malignant disease and the validation of the Charlson
Index in oncology are discussed. For more detailed
reviews of the comorbidity indices outlined in this article,
the authors refer readers to three systematic reviews of
comorbid illness scoring systems by Extermann and de
Groot [2-4].
Comorbidity and cancer
In the 1960's, Feinstein initially reported the prognostic
importance of patient-related characteristics, such as
symptomatology and concurrent illness, in his analyses of
differences between actual survival outcomes and those
predicted by TNM-based staging among lung cancer
patients [5]. In recent years, the direct influence of comor-
bid illness on treatment decision-making and survival
outcomes has been documented for a variety of malignan-
cies including bladder, lung, head and neck, colorectal,
breast, and prostate cancers [6-11].
Hall, et al, for example, evaluated the effect of comorbid-
ity on survival among head and neck cancer patients, con-
cluding that 16% of mortality at 3 years and 18% at 5
years was attributable to comorbid illness alone, with
non-cancer causes of death exceeding cancer-related
causes of death after 7.5 years [6]. Satariano & Ragland
made comparable observations in their study of breast
cancer patients. In their analysis, comorbidity increased
directly with age (p < 0.001) and a significant association
between comorbidity and the type of treatment received
(p < 0.0001) was observed. After controlling for age, can-
cer stage, and type of treatment, increasing comorbidity
remained significantly predictive of increased all-cause-
mortality (1 condition, p = 0.04; and for 2 or 3 conditions,
p < 0.001) [7].
Comorbidity has also demonstrated marked predictive
power for survival and treatment allocation among pros-
tate cancer patients. A Netherlands cancer registry study,
for example, identified comorbidity as the single most
important prognostic factor for 3-year survival, with haz-
ard ratios of 2.0 (95% CI = 1.0–4.3) for a single comorbid
illness and 7.2 (95% CI = 3.1–16.6) for 2 or more comor-
bid conditions, and trends toward fewer radical prostatec-
tomies among men with higher degrees of comorbidity
[8]. Total comorbidity counts have been found to be
strongly predictive of survival among colon cancer
patients as well. In addition to identifying increasing
comorbidity with age (p < 0.0001), Yancik, et al, found
raw counts of comorbid conditions to be strongly predic-
tive of survival when used in a model containing age
group, disease stage, and gender (p = 0.0007), with risk
ratios of 1.11 (95% CI 1.10–1.90) and 1.84 (95% CI
1.39–2.46) for total comorbid illness counts of 5–6 and
7–14 respectively [9]. Additional works by De Marco with
colon cancer patients [10], Firat with lung cancer patients
[11], and Piccirillo with head and neck cancer patients
[12] provide unquestionable support for the importance
of comorbidity on survival and treatment-related compli-
cations among oncology patients.
Although the preceding examples are not intended to pro-
vide a comprehensive review of the influence of comor-
bidity on survival and treatment-related complications in
oncology, they provide a clear demonstration of the effect.
In addition, the themes of increasing comorbidity with
age and the influence of comorbidity on outcomes and
treatment decision-making are illustrated. With these
interactions in mind, the investigation of comorbidity has
become an area of increasing interest in our department.
In particular, we have begun focusing on the use of
comorbidity indices and their application in clinical
research. For a variety of reasons, which will be explained
in forthcoming sections of this work, we have focused onBMC Cancer 2004, 4:94 http://www.biomedcentral.com/1471-2407/4/94
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the Charlson Comorbidity Index as the prototypical index
on which to base this research.
The Charlson Comorbidity Index
The Charlson Index was developed in 1987 based on 1-
year mortality data from internal medicine patients
admitted to a single New York Hospital and was initially
validated within a cohort of breast cancer patients. The
index encompasses 19 medical conditions weighted 1–6
with total scores ranging from 0–37. In the development
phase of the index, mortality for each disease was con-
verted to a relative risk of death within 12 months. A
weight was then assigned to each condition based on the
relative risk (RR); for example, RR <1.2 = weight 0, RR ≥
1.2<1.5 = weight 1, RR ≥ 1.5<2.5 = weight 2, RR ≥ 2.5<3.5
= weight 3, and for 2 conditions (metastatic solid tumor
and AIDS) = weight 6.
From the weighted conditions, a sum score can be tallied
to yield the total comorbidity score. The CCI can be fur-
ther adapted to account for increasing age. In the valida-
tion phase of the CCI, age was also found to be an
independent risk factor for death from a comorbid condi-
tion. As a result, relative risk was calculated to increase by
2.4 for each additional decade of life. In the same cohort,
the relative risk of death for each 1-point increase in CCI
score was 2.3. To account for the effects of increasing age,
one point can be added to the CCI score for each decade
of life over the age of 50 [13].
Reviews of the CCI suggests it has good reliability, excel-
lent correlation with mortality and progression-free sur-
vival outcomes, and is easily modifiable, particularly to
account for the effect of age. The CCI's basic limitations
include preservation of data only for the 19 conditions
listed in the index, the exclusion of non-malignant hema-
tologic disease, such as anemia, and reduced predictive
ability for outcomes < 6-months. The CCI is praised for its
ease of use, short rating time, extractability from other
indices, and widespread use [2,3].
Validation of the Charlson Index
Statistical criteria for the assessment of the validity of a test
include content validity, criterion validity, construct valid-
ity, and reliability [4]. Although a detailed discussion of
statistical tests of validity is beyond the scope of this
review, the assessments provide a basis from which to
begin an analysis of the validity of the Charlson Index.
Statistical criteria of validity, as applied to comorbidity
indices, are ultimately dependent upon the comparison of
comorbidity indices to each other, as well as subjective
assessments of certain criteria, such as content validity
and cutoff points for correlation coefficients. The criteria
are, therefore, in and of themselves, problematic. Despite
these limitations, their application to the common
comorbidity indices has been studied extensively.
In a review of validity among comorbidity indices, de
Groot, et al, systemically identified articles referring to
comorbidity between 1966 and 2000. They compared the
Charlson Index with the Cumulative Illness Rating Scale
(CIRS), Kaplan-Feinstein Index (KFI), and Index of Coex-
istent Disease (ICED) and identified correlation coeffi-
cients of > 0.40, "good" test-retest reliability and
"moderate to good" inter-rater reliability for the CCI [4].
In addition, the Charlson Index correlated significantly
with mortality, disability, readmission, and length of stay
outcomes, suggesting good predictive validity leading de
Groot, et al, to conclude that the Charlson Index, as well
as the ICED, KFI, and CIRS, is a valid and reliable method
for assessing comorbidity in clinical research [4].
A similar review by Extermann suggests the Charlson
Index possesses excellent validity and reliability for use in
clinical research in oncology. Extermann also reported
exceptional predictive validity, correlating the CCI with
outcomes involving mortality risk from weeks to years,
postoperative complications, length of hospital stay, dis-
charge to nursing home, and progression-free survival
among cancer patients. Additionally, inter-rater reliabil-
ity, by various measures, was reported at 0.74 among a
cohort of older general oncology patients and 0.945
within a group of elderly breast cancer patients. Test-retest
reliability was also good, ranging from 0.92 among surgi-
cal patients and 0.86 among the previously mentioned
group of elderly oncology patients. Although Extermann
urges some caution based on the tendency of the CCI to
result in comorbidity scores that are sometimes lower
than those observed with other indices, she concludes that
the CCI is easy to use and "highly suitable for vast cohort
studies but may under-detect significant problems result-
ing in non-lethal endpoints" [2].
The Charlson Index has demonstrated excellent predictive
validity for a variety of clinical outcomes as well as numer-
ous malignancies. As discussed previously, the CCI was
developed using a prospective analysis of 1-year mortality
rates among internal medicine patients and then vali-
dated within a population of 588 breast cancer patients.
In the validation phase of Charlson's original study,
increasing CCI scores were significantly correlated with
increased 10-year mortality within a breast cancer cohort
(χ2 = 163, p < 0.0001), with CCI scores of 0, 1, 2, and 3
predicting 10-year survival rates of 93%, 73%, 52%, and
45%, respectively. In the original manuscript, Charlson, et
al, cautioned that their index should be considered pre-
liminary and that it required validation in larger popula-
tions [13].BMC Cancer 2004, 4:94 http://www.biomedcentral.com/1471-2407/4/94
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Since the original work by Charlson, et al, the CCI has
exhibited substantial prognostic power for both survival
and treatment related complications in numerous retro-
spective studies. Singh, et al, for example, retrospectively
analyzed CCI validity within a cohort of head and neck
cancer patients. Their analysis revealed reduced median
tumor specific survival (12.3 vs. 38.7 months, p = 0.007),
and increased risk of cancer death (RR = 2.35) for patients
with advanced (≥ 2) CCI scores. The CCI compared simi-
larly to the KFI with respect to frequency of advanced
comorbidity (30% for CCI and 32% for KFI) and prognos-
tic power (Spearman correlation coefficient, p <0.001, r =
0.73). However, the CCI was more applicable to the study
population than the KFI, with the KFI successfully applied
to only 80% of the study population compared with
100% application of the CCI [14].
Fowler, et al, also examined the validity of the Charlson
index in a cohort of men with prostate cancer treated with
EBRT or RP. After adjusting for age, a direct relationship
between actuarial survival and CCI score (p = 0.00001)
was found for all patients. Among individuals with CCI
scores of 0, 5 and 10-year survival rates were 86% and
66% compared with 40% and 9% for patients with CCI
scores of 3 to 5. Relative mortality risk, based on CCI
scores of 0, 1, 2, and 3–5, increased from 1 to 1.7, 2.6, and
5.7, respectively [15].
Additional studies among prostate cancer patients have
compared the CCI, KFI, and ICED. Albertsen, et al, for
example, found each of the three comorbidity indices had
similar power to predict survival (p < 0.001 for each), with
the addition of any of the three indices to Gleason score
improving predictive power for survival over Gleason
score alone [16]. We also recently reviewed the impor-
tance of comorbidity and prognostic utility of the CCI
among prostate cancer patients and found that the CCI
consistently correlates with reduced survival as well as
treatment allocation [17].
The Charlson Index has also been validated as a prognos-
tic indicator for survival in lung cancer cohorts. Firat, et al,
recently explored the prognostic importance of comorbid-
ity among patients undergoing surgical resection or defin-
itive EBRT for clinical NSCLC. Within the combined
group, both CIRS-G scores ≥ 4 (p < 0.001) and Charlson
score ≥ 2 (p = 0.004) emerged as significant prognostic
indicators of reduced overall survival. Examination of the
surgical and EBRT groups separately also demonstrated
higher CIRS-G and Charlson scores within the EBRT
group as compared with the surgical group [18].
The effect of comorbidity on complication rates among
lung cancer patients has also been investigated. Brim, et
al, for example, identified gender, CCI score 3–4, COPD,
and prior tumor within the last 5 years as predictors for
major complications (re-thoracotomy, empyema, pleural
effusion, bronchopleural fistula, ventilatory support >72
hours, ventricular arrhythmia, pulmonary embolism, car-
diac failure, or myocardial infarction). Charlson scores of
3–4 maintained statistical significance after multivariate
regression (OR 9.8, 95% CI 2.1–45.9) [19].
CCI scores have also demonstrated prognostic value, both
in terms of postoperative complications and survival
among colon cancer patients. Rieker, et al, found raw CCI
scores reached 0–2, 3–4, and ≥ 5 in 66%, 25%, and 8% of
patients, respectively. With respect to survival, CCI score
>2 emerged as a poor prognostic indicator for overall sur-
vival for all stages (p < 0.001, OR 2.91, 95% CI = 2.00–
4.94). Subgroup analysis of stage III and IV patients
revealed reduced cancer-specific survival among patients
with CCI score >2 (log rank p <0.005). CCI scores > 2 were
also correlated with receipt of blood transfusion (p <
0.021, OR 1.56, 95% CI = 1.07–2.28), postoperative com-
plications (p < 0.001, OR 2.18, 95% CI = 1.50–3.16), and
ICU stay > 2 days (p < 0.001, OR 3.28, 95% CI = 1.91–
5.64) [20].
Taken together, this series of papers represents a diverse
and relatively large experience with the Charlson Index. In
each report, CCI scores consistently correlate with disease
specific survival, overall survival, or treatment-related
complications, confirming its predictive validity.
Implementation
The CCI Calculator provided with this manuscript is
based on the original index proposed by Charlson, et al,
and is available in the section: supplementary material/
table 1/appendix 1 [see 1: CCICalc.xls]. The calculator was
developed using Microsoft Excel/Visual Basic software
and can be downloaded from this journal. Simplicity and
ease of use were the main design objectives.
Presented as a simple Microsoft Excel tool, it can be easily
extended or integrated with other systems that can import
Microsoft Excel data, or imported as a flat file. The Calcu-
lator functions well with both MS Windows and Macin-
tosh operating systems running any Microsoft Excel
version with Macro capabilities and is free to all users of
Biomed Central Cancer. There are no restrictions concern-
ing the use of the calculator software. A running CCI score
can be calculated by selecting the conditions and age
groups within the file. The calculator can be used with or
without age modification as proposed by Charlson, et al
[13]. It is important to note that the upper limit scores for
this calculator are 37 for "age unadjusted" and 43 for "age
adjusted." Charlson scores >8–10 have not received exten-
sive evaluation in the comorbidity literature. We intend
the calculator to be widely distributed so that use of theBMC Cancer 2004, 4:94 http://www.biomedcentral.com/1471-2407/4/94
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CCI can become a routine aspect of clinical research in
oncology.
To use the calculator, the user must select "enable macros"
when prompted to do so as the file opens. To calculate a
CCI score, any of the applicable conditions can be
selected. All selected conditions will then be displayed in
a lighter shade within the table. Corrections can be made
by deselecting conditions, which then removes their
weighted value from the score. The CCI score can then be
totaled, or an age-modified score can be determined by
selecting any one of the applicable "Age by Decade"
groups. Scores totaled without age modification will
appear in the "Age Unadjusted CCI Score" total and no
value will appear in the "Age Adjusted Score" total. Scores
totaled by selecting an age group without selecting a
comorbidity will result in no value for either total and the
user will be prompted to "Reset & Select Condition." To
reset the program, the "Reset CCI Calculator" button can
be selected. The calculator can be further modified as
needed by changing entries in the "Data Sheet" area of the
workbook which is hidden in the read-only version of the
calculator, but can be unhidden by selecting "Format,"
then "Sheet," followed by "Unhide" from the Excel menu.
The "Data Sheet" can then be selected and will be viewa-
ble. To modify the original Macro, users can contact the
authors and the password will be provided on a case-by-
case basis.
Results and discussion
The extensive validation of the CCI as a powerful predic-
tor of clinical outcome combined with its simplicity and
widespread use in oncology have led to the adoption of
the Charlson Index as the prototypical comorbidity index
in our department. In addition to validity, our criteria for
the use of a comorbidity index focus on simplicity in
design, consistency in scoring, and ease of use. It is our
contention that many of the commonly used comorbidity
indices, such as the ICED, CIRS, and KFI have failed to
achieve widespread use because they remain complicated,
cumbersome to use, and poorly accessible for use in clin-
ical research. Given the adaptability of the CCI for the
inclusion of additional variables, such as age, the CCI also
demonstrates marked potential for modification into can-
cer specific comorbidity indices. We have, therefore,
developed a Charlson Comorbidity Calculator based on a
Microscoft Excel File to improve the collection of comor-
bidity data in our department.
Comorbid illness has demonstrated increasing impor-
tance as a prognostic factor for survival and treatment-
related outcomes in oncology. It confounds the results of
clinical trials because the lack of a standardized measure-
ment has resulted in the failure to adjust for comorbidity
in statistical analysis of outcomes data [1,2]. It also limits
the applicability of clinical research to large segments of
the oncology population because protocol designs tend to
exclude older and sicker patients [21,22]. Recent reviews
consistently identify the CCI, ICED, CRIS and KFI as vali-
dated and acceptable measurements of comorbidity and
recommend their use in clinical research. Although the
ICED, CIRS, and KFI obtain superior prognostic power in
some series, the CCI consistently demonstrates statistical
validity, particularly in terms of prognostic validity, and
remains the most structurally simple, easy to use and well-
defined of the comorbidity indices. The ICED and CIRS,
for example, both require coding manuals and training
courses to be used effectively. The KFI has required exten-
sive modification for use in oncology because it was orig-
inally designed to assess comorbidity in diabetic patients.
Recent modifications of the KFI for use in oncology, such
as those applied by Piccirillo in a head and neck cancer
specific modification of the KFI (available in electronic
calculator format at http://oto.wustl.edu/clinepi/
calc.html) also require training courses for effective use
[12]. By contrast, the Charlson Index is intuitive, requiring
users to select a condition from a defined list, rather than
searching for disease value or specific information about
disease severity. In our department, the cumbersome
requirements for use of the ICED, KFI, and CIRS would
reduce compliance with collection of comorbidity data.
Furthermore, the increased training requirements and
intricacies of these indices may increase variability
between scores, as it is unlikely that a single staff member
would be responsible for the collection of all data. It is,
therefore, our belief that the Charlson Index represents
the optimal balance between ease of use and prognostic
ability and has, therefore, become the method of choice
for the collection of comorbidity data in our department.
Accordingly, we developed the CCI calculator to improve
compliance with the collection of comorbidity data and
as a quality assurance tool to ensure that such data is col-
lected correctly and uniformly.
The use of comorbidity data in clinical research is at an
important crossroads, with necessity of its use becoming
imperative as electronic capabilities for its assessment
become more feasible. As the US population gets older,
the use of comorbidity data in clinical trials will only
increase in relevance. Current estimates indicate that the
elderly will comprise 20% of the population by the year
2030 [23]. Studies of older oncology patients also suggest
that the elderly shoulder the majority of cancer burden,
with risk rates 11 times greater than those of younger
patients, with over 50% of all cancer-related mortality
[24]. The rise of comorbidity with increasing age is a
theme common to most retrospective studies of comor-
bidity. In this light, determining the effect of comorbidity
on cancer-related survival and treatment-related compli-
cations has become increasingly important.BMC Cancer 2004, 4:94 http://www.biomedcentral.com/1471-2407/4/94
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Furthermore, evidence to suggest that comorbidity and
performance status represent independent prognostic fac-
tors is accumulating. Extermann, et al, for example, exam-
ined the relationship between comorbidity and
performance status. Both Charlson and CIRS-G were
found to have little or no correlation with ECOG perform-
ance status, activities of daily living (ADL), or instrumen-
tal activities of daily living (IADL). More recently, Repetto,
et al, found that among 269 elderly cancer patients with a
reported ECOG performance score of <2, 13% had 2 or
more comorbidities, 9.3% had ADL limitations, and
37.7% had IADL limitations. Although a statistical corre-
lation between ECOG performance status, number of
comorbidities, and comprehensive geriatric assessment
was identified in univariate analysis, only comorbidity,
ADL limitation and IADL limitation maintained statistical
significance in multivariate analysis. Firat, et al also found
CIRS-G and Karnofsy performace status to be independ-
ent predictors of outcome in their analysis of prognostic
factors in 112 patients enrolled on 4 RTOG trials of stage
III lung cancer [11].
Without widespread integration of comorbidity data into
clinical research, an increasing number of elderly patients,
and their physicians, will be left with treatment recom-
mendations and outcomes data that lack relevance for
their age and level of comorbidity.
Concurrently, electronic medical records (EMR) and data
collection systems are becoming increasingly common
and easy to use, with EMR use among European countries
approaching 60% to 90% [27]. The EMR ultimately prom-
ises increased physician efficiency and improved clinical
outcomes for patients. Contemporary EMR systems have
improved outcomes by reducing errors with the use of
electronic prescribing systems and improving preventative
care with automated reminder systems [28,29]. The MS
Excel CCI Calculator provided with this manuscript, for
example, could easily be integrated into an EMR for aid in
data collection. Such integration would eventually pro-
vide an enormous data pool on which to base future
research on the prognostic importance of CCI.
To our knowledge, this is the first electronic data collec-
tion system offered for the Charlson Comorbidity Index.
The simplicity of the index itself, coupled with the sim-
plicity of MS Excel and the Visual Basic programming lan-
guage, have resulted in a robust electronic CCI calculator
that functions well across both Windows and Macintosh
platforms. The latest version of the calculator, which is
provided with this manuscript, has performed without
error consistently on the first (WH), second (RR) and
third (SN) authors' Windows-based PCs.
The major limitations of the CCI calculator lie in the lim-
itations known to comorbidity indices and to the index
itself. These include lack of understanding as to the rela-
tive importance of various individual conditions on mor-
tality, treatment-related complications and quality of life.
Furthermore, failure to include some conditions with par-
ticular relevance to cancer patients, such as non-malig-
nant hematopoietic disorders and thromboembolic
disorders, as well as uncertainty as to whether a few spe-
cific diseases or the overall disease burden is more impor-
tant for prognosis, remain important considerations
limiting use of the CCI [2,3]. Additionally, the CCI has a
tendency to underscore comorbidity because it is limited
to 19 conditions and because it excludes the primary
malignant condition. For example, in a patient with local-
ized prostate cancer, history of COPD and myocardial inf-
arction, the CCI score calculated by a urologist would
exclude prostate cancer from the calculation resulting in a
score of 2. The same patient might receive a score of 3 by
a cardiologist because myocardial infarction, as opposed
to prostate cancer, was excluded from the calculation.
Another limitation of the CCI lays in the frequent use of
grouped CCI scores, or CCI grades, rather than the use of
scores as continuous variables. Within an elderly cohort in
whom comorbidity is likely to be high, the CCI will have
reduced utility if it lacks the ability to distinguish between
a score of 2, representing mild to moderate comorbidity,
and a score of 8, representing severe comorbidity. With
this limitation in mind, we recommend the use of CCI
score as a continuous variable.
Despite its limitations, the general oncology literature
supports the use of CCI as a prognostic variable in clinical
research. It should be emphasized that the CCI is not
meant to replace clinical experience and its use in clinical
decision-making should be considered investigational.
With additional research, CCI methodological limitations
can be addressed and the index modified to improve
upon its utility. In an effort to improve our understanding
of the CCI and identify areas of the index in need of
improvement, we are currently investigating the effect of
score thresholds on treatment decision-making among
prostate cancer experts. We believe that dissemination of
the MS Excel CCI Macro will lead to increased use of the
CCI for clinical research purposes as well as modification
of the CCI to increase its validity and clinical utility. Ulti-
mately, we hope that the comorbidity indices, such as the
CCI, will see widespread use in clinical research and even-
tual integration into EMRs as a result of these efforts.
Conclusions
The Charlson Comorbidity Index has demonstrated excel-
lent predictive validity in numerous cancer-related out-
come studies. It has met the criteria for statistical validity
as outlined by several authors. In our opinion, the CCIBMC Cancer 2004, 4:94 http://www.biomedcentral.com/1471-2407/4/94
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represents the optimal balance between ease of use and
prognostic ability. Its simplicity in design also makes its
adaptation to include additional variables extremely feasi-
ble. We have, therefore, adopted the CCI as an acceptable
comorbidity measurement tool in our department and
created a Microsoft Excel Macro to facilitate its correct and
uniform use in clinical research.
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